目的 用沙美特罗/丙酸氟替卡松(商品名:舒利迭)联合噻托溴铵(商品名:思力华)治疗分析慢性阻塞性肺疾病(chronic obstructive pulmoriary disease, COPD)的效果。方法 选择2013-2015年确诊为COPD且接受诊治的患者60例,其中接受常规COPD对症治疗方案的患者30例为对照组,另采取沙美特罗/丙酸氟替卡松联合噻托溴铵治疗的30例为观察组。对比两组疗效。结果 对照组总有效率83.3%,观察组总有效率96.7%;观察组高于对照组,差异有统计学意义(P<0.05);观察组FEV₁和FEV₁/FVC均大于对照组,差异有统计学意义(P<0.05);治疗后5个月检测6 min步行距离和生活质量情况,观察组均优于对照组,差异有统计学意义(P<0.05)。结论 用沙美特罗/丙酸氟替卡松联合噻托溴铵方案治疗COPD能提高临床疗效和促进身体功能恢复。

Objective To analyze the clinical significance of treatment of patients with chronic obstructive pulmonary disease (COPD) with seretide combined with spiriva.Methods Sixty patients diagnosed with chronic obstructive pulmonary disease (COPD) and treated between 2013 and 2015 were selected as subjects. Thirty of them received conventional treatment and served as control group while the rest took seretide and spiriva and served as observation group. The clinical efficacy of different intervention programs was compared.Results After treatment, the total effective rate was 83.3% in control group, butwas 96.7% in observation group,and the difference was statistically significant (P<0.05). FEV₁ and FEV₁/FVC of observation group were greater than those of control group, and the difference was statistically significant (P<0.05). After 5 months of treatment,the therapeutic effect was better in observation group than in control group in terms of the 6 min walking distance and quality of life (P<0.05), and the difference was statistically significant.Conclusions In patients with chronic obstructive pulmonary disease (COPD), treatment with seretide combined with spiriva can significantly improve clinical efficacy and recovery of physical functions of patients.